DUAL Antithrombotic Therapy in Patients With AF and ACS

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 4000 participants.

Also called NCT04023630

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 4,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04023630
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04023630. Randomized; no masking; primary purpose treatment. Start 2019-10-01 (anticipated); primary completion 2020-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DUAL Antithrombotic Therapy in Patients With AF and ACS
Condition
Acute Coronary Syndromes
Intervention (Drug)
Rivaroxaban 15 MG Oral Tablet
Intervention (Drug)
Clopidogrel 75 Mg Oral Tablet
Intervention (Drug)
Ticagrelor 90 MG Oral Tablet
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct04023630
Content hash
3bc3e1681b07142af267a6723a37909cf88a6dd7a7d3e5df57ea1982e057bc3b